Abner Antonio Murray, Hematology/Oncology Fellow at UNC School of Medicine, shared on X:
“Sacituzumab tirumotecan (sac-TMT), a novel TROP2-ADC, significantly outperformed docetaxel in previously treated advanced EGFR-mutant NSCLC across all efficacy endpoints:
ORR: 45.1% vs 15.6%
mPFS: 6.9 vs 2.8 mo (HR 0.30, p < 0.0001)
OS: NR vs NR (HR 0.49, p = 0.007)
RPSFT-adjusted OS: NR vs 9.3 mo (HR 0.36)
Subgroup analyses confirmed consistent PFS benefit across mutation type, brain metastases, prior TKI line, and EGFR-TKI generation. mDOR was 7.0 mo.
Safety profile was manageable:
No ILD reported
Most common TRAEs were hematologic (anemia, neutropenia, stomatitis)
No febrile neutropenia in sac-TMT arm
Grade ≥3 TRAEs: 56.0% vs 71.7%
Already approved by China NMPA, sac-TMT is now the first TROP2-ADC approved for lung cancer. Global phase 3 trials (monotherapy + with osimertinib) are ongoing.
This ADC represents a promising new option in the post-EGFR-TKI landscape.”
